DALUPHAR
ActiveSummary
The computed 12-month bankruptcy probability of DALUPHAR is 1.8% (moderate). The 2025 annual accounts show equity of €74,439 and a net result of -€30,135. Equity is shrinking by about 5.6% per year across the filed financial years. Its solvency ranks better than 22% of 5,004 sector peers (NACE 47, financial year 2025). The company has been active since 2003 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
24-03
Gazette deed
Permanent representatives: Mohamad KASSAS and Apostolos STATHOPOULOS3 facts ▸
- General meeting, 16-01-2025
- Permanent representative, Mohamad KASSAS (representative)
- Permanent representative, Apostolos STATHOPOULOS
17-09
Gazette deed
Resignation: Daniel Truyts (director and managing director)Appointment: ERC PHARMA (director and managing director) · Permanent representative: Mohammad Kassas · Registered-office move5 facts ▸
- General meeting, 19-08-2024
- Director resignation, Daniel Truyts (director and managing director)
- Director appointment, ERC PHARMA (director and managing director)
- Permanent representative, Mohammad Kassas
- Registered-office move, Edmond Delcourtstraat 53 - B-1070 Brussel
Show earlier events
About the unread acts
Of the 6 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 4 have not been read yet: what they contain is neither established nor disproved here.